Sun Pharma Advanced Research Company Limited (BOM:532872)
India · Delayed Price · Currency is INR 134.95
-1.95 (-1.42%)
At close: Feb 12, 2026
BOM:532872 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 531.36 | 717.66 | 755.45 | 2,388 | 1,372 | 2,530 |
Revenue | 531.36 | 717.66 | 755.45 | 2,388 | 1,372 | 2,530 |
Revenue Growth (YoY) | -13.08% | -5.00% | -68.36% | 73.98% | -45.74% | 229.31% |
Cost of Revenue | 312.2 | 302 | 364.39 | 283.24 | 235.6 | 328.59 |
Gross Profit | 219.16 | 415.66 | 391.07 | 2,105 | 1,137 | 2,201 |
Selling, General & Admin | 1,852 | 2,454 | 2,944 | 2,390 | 1,658 | 1,457 |
Research & Development | 313.04 | 813.34 | 1,014 | 1,495 | 1,084 | 1,840 |
Other Operating Expenses | 313.27 | 362.97 | 426.59 | 339.19 | 254.38 | 253.45 |
Operating Expenses | 2,585 | 3,753 | 4,508 | 4,341 | 3,098 | 3,658 |
Operating Income | -2,366 | -3,338 | -4,117 | -2,236 | -1,961 | -1,457 |
Interest Expense | -264.47 | -84.57 | -11.75 | -76.35 | -133.29 | -106.5 |
Interest & Investment Income | 6.82 | 6.82 | 254.76 | 75.95 | 14.1 | 8.97 |
Currency Exchange Gain (Loss) | -17.76 | -17.76 | -28.99 | -20.69 | -8.39 | 30.14 |
Other Non Operating Income (Expenses) | 68 | -5.6 | -2.82 | 0.17 | 0.77 | 4.71 |
EBT Excluding Unusual Items | -2,573 | -3,439 | -3,906 | -2,257 | -2,088 | -1,520 |
Gain (Loss) on Sale of Investments | 10.55 | 10.55 | 31.73 | 32.65 | 4.64 | 5.67 |
Gain (Loss) on Sale of Assets | 0.33 | 0.33 | 5.82 | -1.13 | 48.93 | 2.64 |
Other Unusual Items | -123.6 | - | - | - | - | - |
Pretax Income | -2,686 | -3,428 | -3,868 | -2,226 | -2,034 | -1,511 |
Income Tax Expense | -7.12 | -2.72 | 3.82 | - | - | - |
Net Income | -2,679 | -3,425 | -3,872 | -2,226 | -2,034 | -1,511 |
Net Income to Common | -2,679 | -3,425 | -3,872 | -2,226 | -2,034 | -1,511 |
Shares Outstanding (Basic) | 325 | 325 | 325 | 285 | 263 | 262 |
Shares Outstanding (Diluted) | 325 | 325 | 325 | 285 | 263 | 262 |
Shares Change (YoY) | 0.02% | - | 13.99% | 8.19% | 0.42% | - |
EPS (Basic) | -8.25 | -10.55 | -11.93 | -7.82 | -7.73 | -5.77 |
EPS (Diluted) | -8.25 | -10.55 | -11.93 | -7.82 | -7.73 | -5.77 |
Free Cash Flow | - | -3,706 | -4,557 | -845.05 | -2,409 | -1,579 |
Free Cash Flow Per Share | - | -11.42 | -14.04 | -2.97 | -9.15 | -6.03 |
Gross Margin | 41.25% | 57.92% | 51.77% | 88.14% | 82.83% | 87.01% |
Operating Margin | -445.29% | -465.06% | -544.98% | -93.66% | -142.86% | -57.60% |
Profit Margin | -504.20% | -477.26% | -512.56% | -93.22% | -148.20% | -59.75% |
Free Cash Flow Margin | - | -516.45% | -603.21% | -35.39% | -175.53% | -62.42% |
EBITDA | -2,284 | -3,252 | -4,027 | -2,149 | -1,877 | -1,366 |
EBITDA Margin | - | - | - | -89.99% | -136.79% | -54.01% |
D&A For EBITDA | 82.04 | 85.4 | 89.86 | 87.74 | 83.25 | 90.88 |
EBIT | -2,366 | -3,338 | -4,117 | -2,236 | -1,961 | -1,457 |
EBIT Margin | - | - | - | -93.66% | -142.86% | -57.60% |
Revenue as Reported | 622.87 | 735.57 | 1,050 | 2,497 | 1,441 | 2,584 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.